Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06451913 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (Early Skin Form of Lyme Borreliosis))

Study acronym: SUBLYME
StatusRecruiting
PhasePhase 4
SponsorBiocodex
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Dec 2025 to Dec 2026
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 2025 to Jul 16, 2025
    v3
  2. Primary and study completion dates: Jan 2025 to Dec 2025
    • Start date: Jun 2024 to Apr 2025
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Biocodex
6 trials monitored
See all monitored trials
The aim of this study is to assess the effect of Saccharomyces boulardii CNCM I-745 on gut microbiota in patients undergoing antibiotic therapy (in the context of erythema migrans (early skin form of Lyme borreliosis)).
Trial Details
NCT Number NCT06451913
Lead Sponsor Biocodex
Conditions
(from sponsor)		 Erythema Migrans of Lyme Disease
Related terms Erythema Chronicum Migrans, Glossitis, Benign Migratory, Lyme Disease
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov